United States: Funding Litigation And Treatment: Leveling The Playing Field Or Exploiting The Little Guy?

Is litigation funding a creative way to help "the little guy" or the resurrection of a practice that even the Athenians deemed impolitic?1 In an environment where many posit that access to the courts can be at least somewhat dependent on a person's financial viability, does outside financing of litigation level the playing field between the Davids and the Goliaths? Some say yes; some say no. And each side says so vehemently. Those in favor argue that an infusion of funds helps the smaller players pursue more complex, long-term, high-stakes lawsuits. Those opposed maintain that the practice proliferates unmeritorious claims and that reasonable settlements for valid suits would occur more quickly if the stakes were not escalated by monied meddlers with no "skin in the game" other than the bottom dollar (or "first dollars"). Adding to concerns is the fact that there is very little – read: no – regulation over this type of investing. And there is disagreement over whether plaintiffs should have to disclose that they have "investors," who those investors are, what has been told to the investors about the claim, and the amount and contingencies of the investment. While much remains unclear about how this practice will evolve, everyone seems to agree that it will continue to grow.


Third party litigation funding is the practice of an otherwise disinterested investor providing financing to litigants in exchange for a percentage of a successful outcome – whether a jury verdict or a favorable settlement.2 These agreements typically are non-recourse, meaning the investor takes nothing if the plaintiff loses. To justify the shouldering of this risk, some funding contracts call for quite high interest rates.

A new offshoot of litigation funding is treatment or surgical funding. Under this scenario, a plaintiff contractually allows her treating surgeon to discount his bill and sell it to a medical lender, which then places a lien – not just for the discounted note but the entire cost of care – against any legal reward.3 In particular circumstances, liens "can spiral to as much as 10 times what health insurers would pay for the same procedures."4 Some medical funders also offer "concierge" services, such as cash advances, hotel rooms for recovery after the funded surgery, and travel arrangements – also available at high interest rates.5



As noted above, the demarcation lines are pretty starkly drawn. For those in favor, the first "virtue" of litigation finance is that it "can help the powerless avail themselves of our civil justice system."6 Proponents make the unremarkable point that "litigation is expensive," and that funding provides access to the courts for those unable to afford it.7 But is that not the point of contingency fees?

Such funding can go beyond access to the courts, however, and stretch to include living costs8 or operating costs for a business. And any recovery is held hostage until repayment of the loan and the interest. The service also can morph into funding for either uninsured surgeries, deductibles, or surgeries performed by out-of-network doctors.9 The advantage trumpeted for this controversial practice is akin to that for litigation finance – it helps the vulnerable, economically disadvantaged person have access to that which he formerly could not. In this circumstance, the argument is that it facilitates surgery or other treatment by "top doctors."10

Another outcome lauded by advocates is that it helps manage risk – either in a commercial setting 11 or perhaps mass tort. Who, they ask, is better able to handle the uncertainty associated with high litigation costs juxtaposed against a high and likely – but not guaranteed – return? The single company who has this promising claim but perhaps little free excess capital to expend on lawyers? (Again, the question of the purpose of contingency fees arises.) Or ... a litigation finance company/hedge fund? The enthusiasts champion the latter because diversification is protection: "the risk of holding an entire portfolio of litigation claims is lower than the risk of holding a single claim, just like the risk of holding a portfolio of stocks is lower than the risk of holding a single stock."12 Defenders also suggest that a business that monetizes its claim frees itself and its money to stick with – as Michael Corleone said, albeit in a different context – "strictly business."13

Lastly, some supporters claim "litigation finance might actually reduce the time and cost of litigation."14 The idea as espoused is two-fold and, actually, self-contradictory. First, they theorize that defendants will settle more quickly when they realize that a plaintiff is backed by outside funds and able to hold his own in a discovery war of attrition. But such conjecture requires the acknowledgement that "litigation finance might prolong the litigation by allowing for robust discovery."15 The latter outcome is quickly embraced, however, by noting that "there's nothing wrong with that – the record should be properly developed before the parties decide how to resolve the case."16


You know things have gone awry when Spider-Man enters the fray. But yes, even Spidey has gotten caught in "the web of litigation finance."17 Elliott Management Corp., a hedgefund giant, helped bankroll a lawsuit by Stan Lee Media Inc. against Walt Disney Co. over profits made from comic book characters such as Spider-Man. But this investment went belly-up when a federal judge dismissed the lawsuit.18 So does the plight of our hero, who in the movies lives hand to mouth as Peter Parker, epitomize equal access to justice for the little guy? Or was this a bad investment from the start and a lawsuit that never should have been brought?

Some business groups, the U.S. Chamber of Commerce and U.S. Chamber Institute for Legal Reform (ILR) chief among them, say "the practice gives outside undue influence over cases and drives up the cost of litigation."19 According to the ILR, there is no question but that "[l]itigation financing is a sophisticated scheme for gambling on litigation, and its impact on American companies is unambiguous: more lawsuits, more litigation uncertainty, higher settlement payoffs to satisfy cash-hungry funders, and in some instances, even corruption."20

Opposers also note that litigation funders might have conflicting interests. For instance, a funder typically has as part of the agreement that he takes "first dollars."21 This means that he recoups his investment (and generally some percentage on anything above his investment) first before any trickle down of funds to the actual plaintiff or plaintiff's lawyer. If the prospects of the case have dimmed with time and a settlement offer is made that would allow the financier to break even and also perhaps have a little cushion, he might push for resolution despite the fact that the plaintiff takes little to nothing. The flip side of that same bad coin is that "a litigation financier may set a threshold amount for a settlement, which may force the litigation into later stages in the hope of obtaining a larger damage award at trial or through settlement."22

And while proponents of the practice argue, as noted above, that a plaintiff company can focus on its business as opposed to the litigation with the help of outside litigation finance, what of the defendant company? Opponents say it is exactly the opposite as litigation costs increase and "companies may be diverted from investing their own capital in the economic markets and may not be able to invest their own capital into research and development."23 Those increased costs, as we all know, get passed down. Perhaps litigation truly is expensive.


While there are many issues left for discussion, including the legal and ethical implications of funding practices, the role of mass advertising, and how the existence and particulars of these agreements might be discovered24 (all of which, teaser, might be addressed in a later issue), the question here is a pretty simple one: Is litigation funding and surgical funding good for the little guy?

To recap, the person typically predisposed to enter a financing agreement is someone who needs or thinks he needs additional money – whether it's our hero Peter Parker living hand to mouth or a small company going up against a much larger company. The "little guy" already is at a disadvantage and, as critics note, some funders gouge plaintiffs by charging sky high interest rates that leave a paltry amount, if anything, for the plaintiff while ensuring returns sometimes as high as 200% for finance companies.25 Additionally, with that kind of return for investment, even in the light of the risk involved, it is difficult to see how proponents argue with a straight face that the practice will not engender more litigation.

Other potential pitfalls include the very real risk that Plaintiff counsel's independent professional judgment might be affected. In fact, while sounding somewhat ominous but without providing much actual guidance, the ABA warns that "attorneys must approach transactions involving alternative litigation finance with care."26 Conflicts of interest, which are anathema, could abound. They might even unwittingly adhere to defense counsel or judges who would not know it unless the existence and identity of any funder is revealed at the outset.

Perhaps most troubling are the pitfalls attendant to litigation financing's younger brother, surgical funding. Consider the incentives for surgical treatment in this scenario: (1) the plaintiff need not pay for the surgery or claim it on insurance because it is funded by outsiders, (2) the plaintiff has access to a surgeon now billed as a "top doctor," (3) the doctor might have his own separate agreement with the funder that financially incentivizes him to perform more surgeries, and (4) the value of the plaintiff's damages increases with each surgery or subsequent treatment. The potential problems are manifest. First, a plaintiff could be encouraged to have unnecessary treatment because it increases the value of his claim, but costs him nothing ... at the time. Or a plaintiff who truly does need treatment could be forced into signing an unconscionable agreement where he essentially signs away his potential legal recovery. Lastly, a defendant could face artificially inflated damages claims where a funder seeks upwards of 10 times the cost of treatment. It is little wonder that the Consumer Financial Protection Board has been called upon to examine the practices of the medical funding industry.27


One last consideration is this: what effect does financing have on the profession itself? Is it a good thing for our profession or our society in general to allow outsiders to profit on legal disputes? Methinks maybe not. As one author aptly put it:

Over the last century, many have come to see lawsuits as a means of expression, a political weapon and a powerful deterrent against those who might do wrong. And yet creating lawsuits is not the same as creating something like the [Volkswagen] Bug. Litigation is a zerosum industry – every dollar in damages taken home by the winner, minus fees, must be wrung out of the loser. Litigation also helps shape legal precedent, defining the terms under which civil justice may be sought. It's hard to imagine how billions in outside capital won't wind up changing the justice system. The only question is how.28

And how much. At whose peril.


1 Schwartz, Should you be allowed to invest in a lawsuit?, New York Times Magazine (Oct. 22, 2015) (noting "members of Athenian political clubs would back each other in lawsuits against their rivals" until the practice was banned by Emperor Anastasius).

2 General Thurbert Baker, Paying to Play: inside the Ethics and Implications of Third Party litigation Funding, 23 Widener L.J. 230 (2014); see also Bjornlund and Hanofee, How Third-Party litigation Financing May be Affecting Your Practice, For The Defense 18 (July 2015).

3 Frankel and Dye, U.S. business groups call for probe of medical funding industry, Reuters (Aug. 26, 2015).

4 Id.

5 Frankel and Dye, Special Report: Investors profit by funding surgery for desperate women patients, Reuters (Aug. 18, 2015).

6 Lat, 6 Virtues of Litigation Finance, Above the Law (Nov. 24, 2015).

7 Id.

8 Id.

9 Frankel and Dye, Hip implant maker claims surgical funder inflated patients' bills, Reuters (Sept. 28, 2015).

10 See supra Reuters, Special Report.

11 See supra Above the Law, Virtues.

12 Id.; see also Barrett, Hedge Fund Betting on Lawsuits is Spreading, Bloomberg Business (Mar. 18, 2015). In personal injury litigation, however, law firms large enough to handle mass torts typically already have a diversified inventory – thus diluting this argument in this setting.

13 Supra Above the Law, Virtues.

14 Id. (emphasis in original).

15 Id.

16 Id.

17 Copeland, Litigation Finance is a Tangled Web: Just Ask Spider-Man, MoneyBeat Wall Street Journal (Mar. 24, 2014).

18 Id.

19 Id.; see also Lat, 5 Ethical Issues with Litigation Finance, Above the Law (Dec. 2, 2015).

20 Supra Above the Law, 5 Ethical issues (quoting ILR President Lisa A. Rickard).

21 Id.

22 See supra For the Defense.

23 Id.

24 Even Congress is interested in the details of this practice. N ews Releases (Aug. 27, 2015) (noting Senators Chuck Grassley and John Cornyn sent letters of inquiry to three of the largest commercial litigation financing firms) ( http://ww2.cfo.com/legal/2015/08/gop-senators-seek-details-litigation-finance/) (last accessed Feb. 5, 2016).

25 Supra For the Defense; supra Above the Law (5 Ethical Issues).

26 Am. Bar Ass'n Comm'n on Ethics 20/20, Informational Report to the House of Delegates, White Paper on Alternative Litigation Finance (Feb. 2012) (a 39-page single-spaced novella with no less than 163 footnotes).

27 Supra Reuters, U.S. business groups call for probe of medical funding industry.

28 Schwartz, Should you Be Allowed to Invest in a Lawsuit?, New York Times Magazine (Oct. 22, 2015).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.